DURECT Corp DRRX:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:48 AM EST
2.28quote price arrow down-0.03 (-1.30%)
Volume
450
Close
2.31quote price arrow up+0.08 (+3.59%)
Volume
1,766,932
52 week range
0.95 - 2.96

...

Loading . . .

KEY STATS

  • Open2.23
  • Day High2.34
  • Day Low2.22
  • Prev Close2.31
  • 52 Week High2.96
  • 52 Week High Date05/13/20
  • 52 Week Low0.95
  • 52 Week Low Date03/18/20
  • Market Cap510.23M
  • Shares Out220.88M
  • 10 Day Average Volume2.99M
  • Dividend-
  • Dividend Yield-
  • Beta1.49
  • 1 Year % Change20.94

RATIOS/PROFITABILITY

  • EPS (TTM)-0.05
  • P/E (TTM)-46.39
  • Fwd P/E (NTM)-12.69
  • EBITDA (MRQ)-7.403M
  • ROE (MRQ)-32.35%
  • Revenue (MRQ)41.99M
  • Gross Margin (MRQ)88.91%
  • Net Margin (MRQ)-21.85%
  • Debt To Equity (MRQ)59.60%

EVENTS

  • Earnings Date03/04/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest DURECT Corp News

There is no recent news for this security.

Latest DRRX News From Our Partners

QUOTE FINDER

Profile

MORE
Durect Corporation is a biopharmaceutical company with research and development programs. The Company's products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid...
David Hoffmann
Chairman
James Brown
President
Michael Arenberg J.D.
Chief Financial Officer
Address
10260 Bubb Rd
Cupertino, CA
95014-4166
United States